[Crossref] Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V (2022) Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
It is a dosing decision
Bottom line Switching from semaglutide to tirzepatide can be a viable option for individuals seeking enhanced weight loss or improved glycemic control, or those who cannot tolerate semaglutide side effects
Rybelsus (oral semaglutide) Available doses: 3 mg, 7 mg, 14 mg daily
Compared to other GHRH analogs, tesamorelin is particularly notable for its effect on visceral adipose tissue
Inflammation is known to cause an increase in oxidative processes and some autoimmune diseases have been associated with an increase in oxidative stress and a decrease in glutathione levels